Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Genprex ( (GNPX) ) has provided an announcement.
On October 23, 2025, Genprex announced that its research collaborators would present positive preclinical data at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics. The study highlights the effectiveness of Genprex’s lead drug candidate, Reqorsa® Gene Therapy, in treating ALK-EML4 positive non-small cell lung cancer. The data shows that the therapy induces apoptosis in cancer cells and enhances the efficacy of the ALK inhibitor, alectinib, suggesting a potential clinical trial for Reqorsa as a treatment for ALK-EML4 positive translocated NSCLC.
More about Genprex
Genprex, Inc. operates in the biotechnology industry, focusing on developing gene therapies for cancer and diabetes. The company’s primary product is Reqorsa® Gene Therapy, aimed at treating non-small cell lung cancer (NSCLC) and other diseases.
Average Trading Volume: 534,713
Technical Sentiment Signal: Sell
Current Market Cap: $11.55M
See more insights into GNPX stock on TipRanks’ Stock Analysis page.